Glutathione and Fuel Oxidation in Aging

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-23

Study Completion Date

2022-08-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Glutathione is an important antioxidant protein which protects cells from harmful oxidative stress. Elderly humans are known to have elevated oxidative stress and deficiency of glutathione, but it is not known whether there is deficient synthesis of glutathione in muscle tissue of elderly humans.

Mitochondria are engines of cells where food consumed is burned to make energy. Under normal conditions the fuel of choice in the fasted state is fat, but fasted elderly humans are not able to oxidize fat as well as healthy young humans. Elderly humans also have the highest incidence and prevalence of being overweight and obese, and have increased storage of fat in liver and muscle.

This study will help determine whether

1. elderly humans have diminished synthesis of glutathione in the skeletal muscle, and whether this can be improved by supplementing cysteine and glycine (and not an isonitrogenous placebo) in the diet;
2. improving muscle glutathione concentrations can also improve fuel oxidation in aging;
3. improvement of intracellular glutathione concentrations will be associated with a change in total body fat content

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Glutathione (an Antioxidant) and N-Acetylcysteine on Inflammation

NCT01550432

Obesity Hyperlipidemia Insulin Resistance +1 more

COMPLETED NA

Energetics and Function in Older Humans

NCT02348762

Aging Erythrocyte Glutathione Deficiency Muscle Weakness

COMPLETED PHASE1

Glutathione in Mild Cognitive Impairment

NCT03493178

Mild Cognitive Impairment

ACTIVE_NOT_RECRUITING EARLY_PHASE1

GSH Supplementation on Cold/Flu Symptoms in Older Healthy Adults

NCT02316925

Improvement in Immune Cell Function in Elderly Humans

WITHDRAWN NA

Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19

NCT04703036

Covid19

TERMINATED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will be recruited by written informed consent on forms approved by the Institutional Review Board of Baylor College of Medicine at the time of approval of the full protocol. Subjects taking an nonvitamin supplements or lipid lowering medications will stop this 4 weeks before the screening labs and for the entire duration of the study. Fasted subjects will have screening labs (blood count, HbA1c, lipid profile, liver profile, blood urea nitrogen, Creatinine, thyroid stimulating hormone, free t4, cortisol) followed by an oral glucose tolerance test, measures of muscle strength by dynamometry, tests of function (including a 6-min walk test) and body composition scans to measure total body fat. On another occasion, fasted subjects will be undergo stable isotope infusions and other studies in the metabolic research unit to measure concentrations of amino-acids and glutathione in red blood cells and muscle tissue, glutathione synthesis rates in muscle and red cells, plasma and whole-body mitochondrial fatty-acid oxidation, Kreb's cycle function, urine urea nitrogen, plasma reactive oxygen species and F2-isoprostanes, genes of glutathione synthesis and fuel oxidation. Elderly subjects will also have magnetic resonance spectroscopy scan for liver and muscle fat content.

Young subjects will be given dietary cysteine and glycine for 2-weeks and be restudied 2-weeks later. They are then released from the study.

Elderly subjects will be studied for 16 weeks. They will be assigned to receive either cysteine plus glycine, or alanine in a randomized, double-blinded study design. The studies described above will be repeated after 2 weeks and 16 weeks. Subjects will have monthly measures of liver profile, lipid profiles, BUN and creatinine and glutathione.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young controls

Young controls will be studied before and after receiving cysteine and glycine for 2 weeks

Group Type ACTIVE_COMPARATOR

Glycine, cysteine (as n-acetylcysteine), alanine

Intervention Type DIETARY_SUPPLEMENT

Young controls will receive cysteine plus glycine for 2 weeks

The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months

Elderly active

Elderly subjects in the active group will receive glycine plus cysteine (as n-acetylcysteine) for 4 months, and be studied at baseline, 2 weeks and 4 months

Group Type ACTIVE_COMPARATOR

Glycine, cysteine (as n-acetylcysteine), alanine

Intervention Type DIETARY_SUPPLEMENT

Young controls will receive cysteine plus glycine for 2 weeks

The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months

Elderly placebo

Elderly subjects in the placebo group will receive alanine for 4 months, and be studied at baseline, 2 weeks and 4 months

Group Type PLACEBO_COMPARATOR

Glycine, cysteine (as n-acetylcysteine), alanine

Intervention Type DIETARY_SUPPLEMENT

Young controls will receive cysteine plus glycine for 2 weeks

The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycine, cysteine (as n-acetylcysteine), alanine

Young controls will receive cysteine plus glycine for 2 weeks

The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Elderly subjects: age range 61-80y.
2. Young healthy subjects: age range 21-40y

Exclusion Criteria

1. Renal impairment (serum creatinine \>1.5 mg/dL)
2. Liver impairment (liver transaminases \>2x upper limit of normal)
3. Untreated/uncontrolled hyperthyroidism or hypothyroidism
4. Known hypercortisolemia
5. Known diabetes mellitus
6. Hospitalization in the past 3 months
7. BMI \<27 (elderly group)
8. Elderly women on estrogen replacement
9. Known pre-existing coronary artery disease
10. Fasted plasma triglyceride \>300 mg/dl (on lipid lowering medications)
11. Fasted plasma triglyceride \>500 mg/dl (off lipid lowering medications)

Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes